Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease (Q34157492)

31 July 2017

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease (English)

1 reference

31 July 2017

phase III clinical trial

0 references

0 references

William Klunk

5

0 references

Steven H Ferris

object named as

Steven Ferris

10

0 references

Nick C. Fox

object named as

Nick C Fox

3

0 references

Kaj Blennow

4

object named as

Kaj Blennow

1 reference

31 July 2017

2

Reisa Sperling

1 reference

31 July 2017

Stephen Salloway

1

1 reference

31 July 2017

Murray Raskind

6

1 reference

31 July 2017

Marwan Sabbagh

7

1 reference

31 July 2017

Lawrence S Honig

8

1 reference

31 July 2017

Anton P Porsteinsson

9

1 reference

31 July 2017

Marcel Reichert

11

1 reference

31 July 2017

Nzeera Ketter

12

1 reference

31 July 2017

Bijan Nejadnik

13

1 reference

31 July 2017

Volkmar Guenzler

14

1 reference

31 July 2017

Maja Miloslavsky

15

1 reference

31 July 2017

Daniel Wang

16

1 reference

31 July 2017

Yuan Lu

17

1 reference

31 July 2017

Julia Lull

18

1 reference

31 July 2017

Iulia Cristina Tudor

19

1 reference

31 July 2017

Enchi Liu

20

1 reference

31 July 2017

Michael Grundman

21

1 reference

31 July 2017

Eric Yuen

22

1 reference

31 July 2017

Ronald Black

23

1 reference

31 July 2017

H Robert Brashear

24

1 reference

31 July 2017

Bapineuzumab 301 and 302 Clinical Trial Investigators

25

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

The New England Journal of Medicine

31 July 2017

1 reference

31 July 2017

370

1 reference

31 July 2017

322-333

1 reference

31 July 2017

4

1 reference

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Testing the right target and right drug at the right stage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

The Clinical Dementia Rating (CDR): current version and scoring rules

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Pathological verification of ischemic score in differentiation of dementias.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

A new rating scale for Alzheimer's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

A neuropsychological test battery for use in Alzheimer disease clinical trials.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Functional disability in Alzheimer's disease.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

Assessing patient dependence in Alzheimer's disease.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159618

28 October 2018

Identifiers

DOI

10.1056/NEJMOA1304839

1 reference

31 July 2017

1 reference

31 July 2017

1 reference